Video
Dr. Davies discusses data from CheckMate-274 study of nivolumab in urothelial carcinoma
Author(s):
"I think that for patients that have high-risk features after cystectomy, they absolutely should be on nivolumab. I don't think that's a controversial statement anymore," says Benjamin J. Davies, MD.
Video Player is loading.
In this video, Benjamin J. Davies, MD, discusses findings from the study, Disease-free survival with longer follow-up from the CheckMate-274 trial of adjuvant nivolumab in patients after surgery for high-risk muscle-invasive urothelial carcinoma, which was presented at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana. Davies is a professor of urology at the University of Pittsburgh School of Medicine, chief of urology at UPMC Shadyside, and program director of the Urologic Oncology Fellowship.
Related Videos
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Jason Hafron, MD, outlines AUA 2025 session on clinical trial recruitment
Study data point to gender disparities in oncology research citations
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
Optimizing onabotA for OAB: What are some common misconceptions?
Ian Metzler, MD, on the role for telemedicine, digital health tools in stone disease
Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
Related Content
